Your browser doesn't support javascript.
loading
Ag85B with c-di-AMP as mucosal adjuvant showed immunotherapeutic effects on persistent Mycobacterium tuberculosis infection in mice.
Liang, Xuan; Cui, Ruonan; Li, Xue; Ning, Huanhuan; Kang, Jian; Lu, Yanzhi; Zhou, Shan; Huang, Xinying; Peng, Yujun; Zhang, Jingyao; Li, Shiyun; Ma, Yanling; Bai, Yinlan.
Afiliación
  • Liang X; College of Life Sciences, Northwest University, Xi'an, China.
  • Cui R; Department of Microbiology and Pathogen Biology, Air Force Medical University, Xi'an, China.
  • Li X; College of Life Sciences, Northwest University, Xi'an, China.
  • Ning H; Department of Microbiology and Pathogen Biology, Air Force Medical University, Xi'an, China.
  • Kang J; College of Life Sciences, Northwest University, Xi'an, China.
  • Lu Y; Department of Microbiology and Pathogen Biology, Air Force Medical University, Xi'an, China.
  • Zhou S; Department of Microbiology and Pathogen Biology, Air Force Medical University, Xi'an, China.
  • Huang X; Military Medical Innovation Center, Air Force Medical University, Xi'an, China.
  • Peng Y; Department of Microbiology and Pathogen Biology, Air Force Medical University, Xi'an, China.
  • Zhang J; Department of Microbiology and Pathogen Biology, Air Force Medical University, Xi'an, China.
  • Li S; Department of Clinical Laboratory, Xijing Hospital, Air Force Medical University, Xi'an, China.
  • Ma Y; Student Brigade, Basic Medical School, Air Force Medical University, Xi'an, China.
  • Bai Y; Student Brigade, Basic Medical School, Air Force Medical University, Xi'an, China.
Braz J Med Biol Res ; 57: e13409, 2024.
Article en En | MEDLINE | ID: mdl-38958367
ABSTRACT
Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains the leading cause of mortality by a single infectious agent in the world. M. tuberculosis infection could also result in clinical chronic infection, known as latent TB infection (LTBI). Compared to the current limited treatment, several subunit vaccines showed immunotherapeutic effects and were included in clinical trials. In this study, a subunit vaccine of Ag85B with a novel mucosal adjuvant c-di-AMP (Ag85Bc-di-AMP) was delivered intranasally to a persistent M. tuberculosis H37Ra infection mouse model, which also presented the asymptomatic characteristics of LTBI. Compared with Ag85B immunization, Ag85Bc-di-AMP vaccination induced stronger humoral immune responses, significantly higher CD4+ T cells recruitment, enhanced Th1/Th2/Th17 profile response in the lung, decreased pathological lesions of the lung, and reduced M. tuberculosis load in mice. Taken together, Ag85Bc-di-AMP mucosal route immunization provided an immunotherapeutic effect on persistent M. tuberculosis H37Ra infection, and c-di-AMP, as a promising potential mucosal adjuvant, could be further used in therapeutic or prophylactic vaccine strategies for persistent M. tuberculosis infection as well as LTBI.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adyuvantes Inmunológicos / Vacunas contra la Tuberculosis / Modelos Animales de Enfermedad / Mycobacterium tuberculosis Límite: Animals Idioma: En Revista: Braz J Med Biol Res Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Brasil
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adyuvantes Inmunológicos / Vacunas contra la Tuberculosis / Modelos Animales de Enfermedad / Mycobacterium tuberculosis Límite: Animals Idioma: En Revista: Braz J Med Biol Res Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Brasil